Alibaba Group Holding Limited vs Cardinal Health, Inc.: Strategic Comparison

This in-depth comparison examines Alibaba Group Holding Limited and Cardinal Health, Inc. across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching Alibaba Group Holding Limited on its own, evaluating Cardinal Health, Inc., or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between Alibaba Group Holding Limited and Cardinal Health, Inc. is widest.

On the headline numbers, Alibaba Group Holding Limited reports annual revenue of ~$142.3B against $254.2B for Cardinal Health, Inc., while their respective market capitalizations stand at $266.6B and $56.0B. Alibaba Group Holding Limited is headquartered in China and Cardinal Health, Inc. in United States, and those different home markets shape how each company competes.

Alibaba Group Holding Limited: Alibaba is the leader of Chinese e-commerce and cloud computing. Often lazily compared to Amazon, Alibaba is actually fundamentally different: they don't generally own their own inventory. Instead, they operate large digital marketplaces (like Taobao and Tmall) that connect hundreds of millions of Chinese consumers directly with merchants and factories. Beyond retail, Alibaba is a sprawling tech empire encompassing cloud infrastructure, digital media, logistics, and historically, a deep connection to the fintech giant Ant Group.

Cardinal Health, Inc.: Cardinal Health, based in Ohio, is one of the three large US pharmaceutical distributors, along with McKesson and Cencora. It does not invent drugs or treat patients. It runs the regulated supply chain that moves medicines and medical devices from manufacturers to pharmacies and hospitals, so a prescription collected at a local pharmacy has often passed through its network.

Alibaba Group Holding Limited and Cardinal Health, Inc. pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between Alibaba Group Holding Limited and Cardinal Health, Inc..

Alibaba Group Holding Limited business model: Alibaba earns revenue from customer-management services and commissions on its China commerce marketplaces, direct sales and logistics services in international commerce, cloud products and services, Cainiao logistics, local services, and digital media. Taobao and Tmall primarily connect merchants with consumers rather than operating only as first-party retailers.

Cardinal Health, Inc. business model: The business model is large, high-volume logistics divided into two segments: Pharmaceutical and Medical. In the Pharma segment, they buy billions of dollars of drugs from manufacturers (like Pfizer) and distribute them daily to tens of thousands of pharmacies and hospitals, taking a tiny markup. In the Medical segment, they actually manufacture and distribute low-cost, high-volume medical supplies (like surgical gloves, gowns, and syringes), acting as the large central supply closet for the entire American hospital system.

The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of Alibaba Group Holding Limited stack up against those of Cardinal Health, Inc..

Alibaba Group Holding Limited competitive advantage: Alibaba's primary moat was its large network effect within China; virtually every merchant had to be on Taobao because that's where all the consumers were, and vice versa. their proprietary logistics network (Cainiao) and deep integration with Alipay created a frictionless ecosystem for Chinese consumers. While that moat has been weakened recently by fierce competitors like Pinduoduo and ByteDance (Douyin), Alibaba still possesses leading scale, consumer data, and cloud computing infrastructure in the region.

Cardinal Health, Inc. competitive advantage: Cardinal Health's advantage is physical scale and regulatory standing. Moving regulated, temperature-sensitive drugs and biologics across the country overnight takes a network of specialized distribution centers and security procedures that cost billions of dollars and take decades to build. The barrier to entry is high, so drug distribution is concentrated among a few large companies.

Future prospects matter as much as current results. The growth strategies below explain how Alibaba Group Holding Limited and Cardinal Health, Inc. each plan to expand from here.

Alibaba Group Holding Limited growth strategy: Facing intense regulatory scrutiny and fierce domestic competition, Alibaba's growth strategy recently underwent a large structural overhaul. They announced a plan to split the empire into six separate, independent business groups (like Cloud, E-commerce, and Logistics), allowing each to operate faster and potentially seek their own IPOs. Strategically, they are heavily focused on defending their domestic e-commerce turf through deep discounting, while aggressively pushing their 'Alibaba Cloud' division to capture the booming Chinese enterprise AI market.

Cardinal Health, Inc. growth strategy: Cardinal Health's growth plan rests on three levers. First, specialty pharmaceuticals and physician practice platforms: it bought a 71% stake in GI Alliance for about $2.8 billion (announced November 2024) and funded The Specialty Alliance's roughly $1.9 billion acquisition of urology MSO Solaris Health (completed November 2025). Second, the Other segment: Nuclear and Precision Health Solutions (radiopharmaceuticals and theranostics), at-Home Solutions (expanded with ADSG in 2025, Strive Medical, and the announced AdaptHealth diabetes business), and OptiFreight Logistics, which together grew revenue 26% to $6.8 billion in fiscal 2026. Third, improving GMPD profitability through its Cardinal Health brand products and cost actions.

A closer look at the financial trajectory of Alibaba Group Holding Limited and Cardinal Health, Inc. rounds out the comparison.

Alibaba Group Holding Limited: Revenue rose from ~$22 billion (RMB158.3 billion) in FY2017 to ~$142 billion (RMB1.024 trillion) in FY2026. Net income was ~$14.4 billion (RMB103.6 billion) in FY2026, down from ~$17.5 billion (RMB126.0 billion) in FY2025. Alibaba reports on a March 31 fiscal year and invests heavily in commerce, cloud and AI infrastructure.

Cardinal Health, Inc.: Cardinal Health combines very large revenue with thin margins. Fiscal 2026 revenue was $254.2 billion, up 14% from $222.6 billion in fiscal 2025, driven by brand and specialty drug volume from existing customers. GAAP operating earnings were $2.6 billion, GAAP diluted EPS was $7.23, and net earnings attributable to Cardinal Health were about $1.7 billion. Non-GAAP diluted EPS rose 37% to $11.26 ($10.95 excluding the IEEPA tariff refund). Operating cash flow was $5.2 billion and adjusted free cash flow was $5.0 billion. The company repurchased $1.4 billion of stock in fiscal 2026 and the board added $5.0 billion to the buyback authorization in August 2026. Fourth-quarter fiscal 2026 revenue was $63.7 billion, up 6%.